747413-17-8

Basic information

• Product Name: 1-(3-broMophenyl)-4-Methylpiperazine
• Synonyms: 1-(3-broMophenyl)-4-Methylpiperazine;Piperazine,1-(3-bromophenyl)-4-methyl-;1-bromo-3-(4-methyl-1-piperazinyl)benzene
• CAS NO: 747413-17-8
• Molecular Formula: C₁₁H₁₅BrN₂
• Molecular Weight: 255.1542
• EINECS: -0
• Mol File: 747413-17-8.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3-broMophenyl)-4-Methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-broMophenyl)-4-Methylpiperazine(747413-17-8)
• EPA Substance Registry System: 1-(3-broMophenyl)-4-Methylpiperazine(747413-17-8)

Safety Data

• Hazardous Substances Data: 747413-17-8(Hazardous Substances Data)

Usage

Uses

1-(3-Bromophenyl)-4-methylpiperazine is used in the optimization of the physicochemical properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation.

Upstream product

• 110-88-3 1,3,5-Trioxan 
• 31197-30-5 1-(3-bromophenyl)piperazine 
• 50-00-0 formaldehyd 
• 109-01-3 1-methyl-piperazine 
• 591-18-4 1-Bromo-3-iodobenzene 
• 108-36-1 1,3-dibromobenzene 

Downstream Products

• 747413-18-9 1-methyl-4-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]piperazine 
• 1257707-00-8 {8-[4-(dimethylphosphinoyl)phenyl]-[1,2,4]triazolo[1,5-a]-pyridin-2-yl}-[3-(4-methylpiperazin-1-yl)phenyl]amine 
• 1257709-19-5 [8-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4-methylpiperazin-1-yl)phenyl]amine 
• 1257704-81-6 [3-(4-methylpiperazin-1-yl)phenyl]-{8-[4-(propane-2-sulfonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}amine 
• 1257704-99-6 [3-(4-methylpiperazin-1-yl)phenyl]-[8-(4-trifluoromethylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amine 
• 1257704-57-6 {[8-(4-methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]-pyridin-2-yl]-[3-(4-methyl-piperazin-1-yl)-phenyl]-amine} 
• 1350659-91-4 8-fluoro-4-[5-[3-(4-methylpiperazin-1-yl)phenoxy]pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1350660-04-6 1-[3-(2-chloropyrimidin-5-yloxy)phenyl]-4-methylpiperazine 
• 1139717-76-2 (3-(4-methylpiperazin-1-yl)phenyl)boronic acid 
• 1286756-81-7 C₃₁H₃₁N₅O₂ 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS

A compound of formula (I) for use in the prevention or treatment of a bacterial infection.

Synthesis and structure-activity relationship analysis of 5-HT7 receptor antagonists: Piperazin-1-yl substituted unfused heterobiaryls

A series of piperazin-1-yl substituted unfused heterobiaryls was synthesized as ligands of the 5-HT7 receptors. The goal of this project was to elucidate the structural features that affect the 5-HT7 binding affinity of this class of compounds represented by the model ligand 4-(3-furyl)-2-(4-methylpiperazin-1-yl)pyrimidine (2). The SAR studies included systematical structural changes of the pyrimidine core moiety in 2 to quinazoline, pyridine and benzene, changes of the 3-furyl group to other heteroaryl substituents, the presence of various analogs of the 4-methylpiperazin-1-yl group, as well as additional substitutions at positions 5 and 6 of the pyrimidine. Substitution of position 6 of the pyrimidine in the model ligand with an alkyl group results in a substantial increase of the binding affinity (note a change in position numbers due to the nomenclature rules). It was also demonstrated that 4-(3-furyl) moiety is crucial for the 5-HT7 binding affinity of the substituted pyrimidines, although, the pyrimidine core can be replaced with a pyridine ring without a dramatic loss of the binding affinity. The selected ethylpyrimidine (12) and butylpyrimidine (13) analogs of high 5-HT7 binding affinity showed antagonistic properties in cAMP functional test and varied selectivity profile-compound 12 can be regarded as a dual 5-HT7 /5-HT2A R ligand, and 13 as a multi-receptor (5-HT7 , 5-HT2A , 5-HT6 and D2 ) agent.